Evidence map›Paper›PMID 42761229›Full record

ArticleKidney international reports2026

Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement.

Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J Vargas-Brochero, Charat Thongprayoon, Jose A Meade-Aguilar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cristián JuanetDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Isabel HassiDivision of Rheumatology, Universidad de los Andes, Santiago, Chile.
Anila CaraDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Cristina García MajadoDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Jose Arriola-MontenegroDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Trisha LaxamanaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Gian Marco BertiDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Maria J Vargas-BrocheroDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Charat ThongprayoonDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Jose A Meade-AguilarDivision of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Samuel D FaldeDivision of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Ulrich SpecksDivision of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Fernando C FervenzaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Ladan ZandDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Avacopan has shown efficacy as a glucocorticoid-sparing therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but its benefit in patients with severe renal involvement treated with rituximab remains uncertain. Methods: We conducted a retrospective comparative cohort study at Mayo Clinic including patients with AAV and estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.73 m Results: Baseline characteristics were well balanced. Median eGFR was 15.0 and 16.0 mL/min/1.73 m Conclusions: In our cohort of patients with AAV and severe renal involvement treated with rituximab-based induction, avacopan did not improve renal remission rates or longitudinal eGFR trajectory in comparison to glucocorticoids but achieved significant and faster glucocorticoid reduction with an acceptable safety profile.

Indexed as

ANCA-associated vasculitisavacopanglucocorticoidrapidly progressive glomerulonephritisrituximabsevere renal involvement

Identifiers

PMID42761229
PMCPMC13586681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.